This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fleming, R. A. Articles by Demard, F. Search for Related Content PubMed PubMed Citation Articles by Fleming, R. A. Articles by Demard, F.

Correlation between Dihydropyrimidine Dehydrogenase Activity in Peripheral Mononuclear Cells and Systemic Clearance of Fluorouracil in Cancer Patients¹

Centre Antoine Lacassagne, Nice 06054, France

Dihydropyrimidine dehydrogenase (DPD) is the initial key enzyme in the catabolism of 5-fluorouracil (5-FU). We measured DPD activity in lymphocytes from 57 consecutive head and neck cancer patients while simultaneously monitoring 5-FU pharmacokinetics during 5-day, continuous infusion (1000 mg/m²/day) 5-FU therapy (82 cycles in total). The mean value for DPD activity was 0.186 ± 0.068 (SD) nmol/min/mg of protein (range, 0.058 to 0.357). The mean value for 5-FU clearance was 2522.6 ± 684.2 ml/min/m² (range, 1052 to 4029). A significant linear correlation was observed between DPD activity and 5-FU clearance (r = 0.716, P < 0.0001). DPD activity was poorly correlated to plasma uracil concentrations (r = –0.260, P = 0.0215). Likewise, plasma uracil concentrations were poorly correlated to 5-FU clearance (r = -0.214, P = 0.0595). In patients evaluated for more than one cycle (n = 18), there was large intrapatient variability in both DPD activity and 5-FU clearance. No significant difference was noted between cycles for DPD activity or 5-FU clearance (Kruskal-Wallis test). Monitoring DPD activity in lymphocytes may be useful in identifying patients at risk for altered 5-FU disposition.

¹ Funded by the Ligue Nationale Francaise contre le Cancer.

² Recipient of a Chateaubriand Scholarship from the Mission Scientifique, Ambassade de France. Present address: Comprehensive Cancer Center of Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27609.

³ To whom requests for reprints should be addressed, at Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, 36 voie Romaine, 06054 Nice Cedex, France.

Received 10/16/91. Accepted 3/10/92.

This article has been cited by other articles:

				R. S. Huang and M. J. Ratain Pharmacogenetics and pharmacogenomics of anticancer agents CA Cancer J Clin, January 1, 2009; 59(1): 42 - 55. [Abstract] [Full Text] [PDF]

				R. Svobaite, I. Solassol, F. Pinguet, L. Ivanauskas, J. Bres, and F. M. M. Bressolle HPLC with UV or Mass Spectrometric Detection for Quantifying Endogenous Uracil and Dihydrouracil in Human Plasma Clin. Chem., September 1, 2008; 54(9): 1463 - 1472. [Abstract] [Full Text] [PDF]

				E. Gamelin, R. Delva, J. Jacob, Y. Merrouche, J. L. Raoul, D. Pezet, E. Dorval, G. Piot, A. Morel, and M. Boisdron-Celle Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer J. Clin. Oncol., May 1, 2008; 26(13): 2099 - 2105. [Abstract] [Full Text] [PDF]

				M. Schwab, U. M. Zanger, C. Marx, E. Schaeffeler, K. Klein, J. Dippon, R. Kerb, J. Blievernicht, J. Fischer, U. Hofmann, et al. Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group J. Clin. Oncol., May 1, 2008; 26(13): 2131 - 2138. [Abstract] [Full Text] [PDF]

				A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M. C. Craipeau, S. Traore, and E. Gamelin Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther., November 1, 2006; 5(11): 2895 - 2904. [Abstract] [Full Text] [PDF]

				M Gusella, G Crepaldi, C Barile, A Bononi, D Menon, S Toso, D Scapoli, L Stievano, E Ferrazzi, F Grigoletto, et al. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer Ann. Onc., November 1, 2006; 17(11): 1656 - 1660. [Abstract] [Full Text] [PDF]

				S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]

				K. R. Crews Individualizing chemotherapeutic treatment of colorectal cancer Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S12 - S17. [Abstract] [Full Text] [PDF]

				L. K. Mattison, J. Fourie, Y. Hirao, T. Koga, R. A. Desmond, J. R. King, T. Shimizu, and R. B. Diasio The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil Clin. Cancer Res., January 15, 2006; 12(2): 549 - 555. [Abstract] [Full Text] [PDF]

				K. Seck, S. Riemer, R. Kates, T. Ullrich, V. Lutz, N. Harbeck, M. Schmitt, M. Kiechle, R. Diasio, and E. Gross Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals Clin. Cancer Res., August 15, 2005; 11(16): 5886 - 5892. [Abstract] [Full Text] [PDF]

				M. Inada, Y. Hirao, T. Koga, M. Itose, J.-i. Kunizaki, T. Shimizu, and H. Sato RELATIONSHIPS AMONG PLASMA [2-13C]URACIL CONCENTRATIONS, BREATH 13CO2 EXPIRATION, AND DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) ACTIVITY IN THE LIVER IN NORMAL AND DPD-DEFICIENT DOGS Drug Metab. Dispos., March 1, 2005; 33(3): 381 - 387. [Abstract] [Full Text] [PDF]

				H. Jiang, J. Lu, J. Jiang, and P. Hu Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics J. Clin. Pharmacol., November 1, 2004; 44(11): 1260 - 1272. [Abstract] [Full Text] [PDF]

				S. E. Bellibas, I. Patel, E. Chamorey, B. Brivet, E. D. Bush, C. Kircher, S. Nave, L. Banken, N. Renee, and G. Milano Single Ascending Dose Tolerability, Pharmacokinetic-Pharmacodynamic Study of Dihydropyrimidine Dehydrogenase Inhibitor Ro 09-4889 Clin. Cancer Res., April 1, 2004; 10(7): 2327 - 2335. [Abstract] [Full Text] [PDF]

				N. Magne, X. Pivot, M. C. Etienne-Grimaldi, E. Francois, N. Renee, A. Thyss, M. Schneider, F. Demard, and G. Milano Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients Ann. Onc., August 1, 2003; 14(8): 1329 - 1330. [Full Text] [PDF]

				Y. Mizutani, H. Wada, O. Yoshida, M. Fukushima, M. Nonomura, M. Nakao, and T. Miki Significance of Thymidylate Synthase Activity in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1453 - 1460. [Abstract] [Full Text] [PDF]

				A. A. Adjei, J. M. Reid, R. B Diasio, J. A. Sloan, D. A. Smith, J. Rubin, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, et al. Comparative Pharmacokinetic Study of Continuous Venous Infusion Fluorouracil and Oral Fluorouracil With Eniluracil in Patients With Advanced Solid Tumors J. Clin. Oncol., March 15, 2002; 20(6): 1683 - 1691. [Abstract] [Full Text] [PDF]

				T.-S. Yang, K.-C. Hsu, H.-M. Wang, and Y.-C. Lin Phase II Study of a Weekly 8-Hour 5-Fluorouracil and Leucovorin Infusion for Patients with Advanced Colorectal Cancer: Dose Adjusted According to its Toxicity Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 610 - 615. [Abstract] [Full Text] [PDF]

				M. Raida, W. Schwabe, P. Hausler, A. B. P. Van Kuilenburg, A. H. Van Gennip, D. Behnke, and K. Hoffken Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5'-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)- related Toxicity Compared with Controls Clin. Cancer Res., September 1, 2001; 7(9): 2832 - 2839. [Abstract] [Full Text] [PDF]

				S. Hiroyasu, M. Shiraishi, H. Samura, H. Tokashiki, H. Shimoji, T. Isa, and Y. Muto Clinical Relevance of the Concentrations of Both Pyrimidine Nucleoside Phosphorylase (PyNPase) and Dihydropyrimidine Dehydrogenase (DPD) in Colorectal Cancer Jpn. J. Clin. Oncol., February 1, 2001; 31(2): 65 - 68. [Abstract] [Full Text] [PDF]

				R. Yoshikawa, M. Kusunoki, H. Yanagi, M. Noda, J.-i. Furuyama, T. Yamamura, and T. Hashimoto-Tamaoki Dual Antitumor Effects of 5-Fluorouracil on the Cell Cycle in Colorectal Carcinoma Cells: A Novel Target Mechanism Concept for Pharmacokinetic Modulating Chemotherapy Cancer Res., February 1, 2001; 61(3): 1029 - 1037. [Abstract] [Full Text]

				S. D. Baker, R. B. Diasio, S. O’Reilly, V. S. Lucas, S. P. Khor, S. E. Sartorius, R. C. Donehower, L. B. Grochow, T. Spector, J. A. Hohneker, et al. Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil J. Clin. Oncol., February 14, 2000; 18(4): 915 - 915. [Abstract] [Full Text] [PDF]

				A. B.P. Van Kuilenburg, H. Van Lenthe, A. Tromp, P. C.J. Veltman, and A. H. Van Gennip Pitfalls in the Diagnosis of Patients with a Partial Dihydropyrimidine Dehydrogenase Deficiency Clin. Chem., January 1, 2000; 46(1): 9 - 17. [Abstract] [Full Text] [PDF]

				C. H. Takimoto, L. K. Yee, D. J. Venzon, B. Schuler, F. Grollman, C. Chabuk, J. M. Hamilton, A. P. Chen, C. J. Allegra, and J. L. Grem High Inter- and Intrapatient Variation in 5-Fluorouracil Plasma Concentrations during a Prolonged Drug Infusion Clin. Cancer Res., June 1, 1999; 5(6): 1347 - 1352. [Abstract] [Full Text] [PDF]

				R. J.A. Harte, J. C. Matthews, S. M. O'Reilly, D.W. O. Tilsley, S. Osman, G. Brown, S. J. Luthra, F. Brady, T. Jones, and P. M. Price Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With N-Phosphonacetyl-L-aspartate, Folinic Acid, and Interferon Alfa J. Clin. Oncol., May 1, 1999; 17(5): 1580 - 1580. [Abstract] [Full Text] [PDF]

				E. Gamelin, M. Boisdron-Celle, V. Guerin-Meyer, R. Delva, A. Lortholary, F. Genevieve, F. Larra, N. Ifrah, and J. Robert Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage J. Clin. Oncol., April 1, 1999; 17(4): 1105 - 1105. [Abstract] [Full Text] [PDF]